🏢 官网IRLUNGCodex · 实盘不做把握 2/10
北京时间·🕒 发布 04:05:49时区推断·⟳ 抓取 04:08:37回填·⚡ 决策 07-16 04:09:24·104.1 天前
Pulmonx宣布将于7月29日盘后发布2026年二季度财报
这只是公司官方发布的财报日期和电话会安排,未披露收入、利润、指引或任何业务超预期信息。
📄 原文LUNG↗ 原文
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Skip to main navigation English Deutsch Español Français Italiano News Release News Releases Events and Presentations «…
不做 Pulmonx(LUNG.US)
例行财报发布时间通知,没有业绩结果、指引修正、订单或监管进展,方向无法确立,当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-15 · 扩散 low · price-in 风险 low ↗
关键理由
- 这只是公司官方发布的财报日期和电话会安排,未披露收入、利润、指引或任何业务超预期信息。
主要风险
- 真正可交易信息要等2026年7月29日盘后财报和管理层电话会披露。
原文全文
展开原文 · 3,395 字
Skip to main navigation
English
Deutsch
Español
Français
Italiano
News Release
News Releases
Events and Presentations
« Back
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Jul 15, 2026
PDF Version
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr ® Endobronchial Valve, Chartis ® Pulmonary Assessment System and StratX ® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com .
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
Print Page
Print Page
Email Alerts
Email Alerts
Contact IR
Contact IR
RSS Feeds
RSS Feeds
In order to provide you with an optimal website experience, we use cookies. By clicking "Accept" you agree to the use of cookies. Further information can be found in our privacy policy . Accept
Privacy & Cookies Policy
Close
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
English
Deutsch
Español
Français
Italiano
News Release
News Releases
Events and Presentations
« Back
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Jul 15, 2026
PDF Version
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr ® Endobronchial Valve, Chartis ® Pulmonary Assessment System and StratX ® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com .
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
Print Page
Print Page
Email Alerts
Email Alerts
Contact IR
Contact IR
RSS Feeds
RSS Feeds
In order to provide you with an optimal website experience, we use cookies. By clicking "Accept" you agree to the use of cookies. Further information can be found in our privacy policy . Accept
Privacy & Cookies Policy
Close
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。